乳腺癌晚期患者循环肿瘤细胞表型Vimentin mRNA与AKT1 mRNA水平表达对临床疗效评估的价值研究  

Value of Circulating Tumor Cell Phenotype Vimentin mRNA and AKT1 mRNA Expression in the Evaluation of Clinical Efficacy in Patients with Advanced Breast Cancer

作　　者：欧阳航 陈德波[2] 骆时木 杨培东 吴一波[1] 张志珊[1] OUYANG Hang;CHEN De-bo;LUO Shi-mu;YANG Pei-dong;WU Yi-bo;ZHANG Zhi-shan(Department of Clinical Laboratory,the First Hospital of Quanzhou Affiliated to Fujian Medical University,Fujian Quanzhou 362000,China;Department of Breast Surgery,the First Hospital of Quanzhou Affiliated to Fujian Medical University,Fujian Quanzhou 362000,China)

机构地区：[1]福建医科大学附属泉州第一医院检验科,福建泉州362000 [2]福建医科大学附属泉州第一医院乳腺外科,福建泉州362000

出　　处：《现代检验医学杂志》2021年第5期73-76,82,共5页Journal of Modern Laboratory Medicine

基　　金：福建省卫生计生委中青年骨干人才培养项目(2017-ZQN-77)。

摘　　要：目的探讨乳腺癌晚期患者外周血中循环肿瘤细胞(circulating tumor cells,CTC)表型标志物波形蛋白(Vimentin)mRNA与蛋白激酶B(protein kinase B,AKT1)mRNA表达水平与患者治疗疗效的相关性。方法收集2018年6月~2020年1月在福建医科大学附属泉州第一医院乳腺外科就诊且初次确诊为晚期乳腺癌的患者共43例,同时选择15例健康体检者作为对照组。每次分别在患者治疗前以及经过2个治疗周期结束后采集外周血标本7.5ml,经差相富集法富集CTC后检测其Vimentin mRNA及AKT1 mRNA的表达情况,并据实体瘤疗效评价标准1.1(response evaluation criteria in solid tumors,RECIST)进行疗效评估。实验所得数据使用SPSS20.0统计软件进行数据分析,GraphPad Prism 7.0软件进行数据的作图。结果晚期乳腺癌患者Vimentin mRNA和AKT1 mRNA的相对表达量均高于健康对照组(t=2.841,2.480,均P<0.05)。患者治疗后Vimentin mRNA和AKT1 mRNA相对表达量低于治疗前,差异均有统计学意义(t=2.879,2.282,均P<0.05),且治疗后Vimentin mRAN表达量下降患者有更高的治疗有效率(P<0.05)。结论晚期乳腺癌患者治疗后Vimentin mRNA和AKT1 mRNA表达量均显著降低,且治疗后Vimentin mRNA表达量降低与更高的治疗疗效有关,提示治疗前后Vimentin mRNA的变化可用于评估患者治疗疗效。Objective To study the expression of circulating tumor cells phenotype markers Vimentin mRNA and AKT1 mRNA in the peripheral blood of patients with advanced breast cancer and their correlation with disease activity therapeutic.Methods From June 2018 to January 2020,43 patients diagnosed as advanced breast cancer were collected from the First Hospital of Quanzhou Affiliated to Fujian Medical University.At the same time,15 healthy subjects were selected as the control group.7.5 ml of peripheral blood samples were collected before treatment and after two cycles of treatment.Detected the expression of Vimentin mRNA and protein kinase B(AKT1)mRNA after enrichment of CTC by differential enrichment method.According to the response evaluation criteria in solid tumors(RECIST),the therapeutic effect was evaluated.SPSS20.0 statistical software was used for data analysis,and GraphPad Prism 7.0 software was used for data mapping.Results The relative expression of Vimentin and AKT1 mRNA in advanced breast cancer group was higher than that in healthy control group,the differences were statistically significant(t=2.841,2.480,all P<0.05).After treatment of advanced breast cancer patients,the relative expression of Vimentin and AKT1 mRNA were significantly reduced(t=2.879,2.282,all P<0.05),and the patients with decreased Vimentin expression had higher therapeutic efficiency(P<0.05)Conclusion The expression levels of Vimentin mRNA and AKT1 mRNA in patients with advanced breast cancer were significantly decreased after treatment,and the decreased expression of Vimentin mRNA was related to the higher therapeutic effect,which suggesting that the changes of Vimentin mRNA could be used to evaluate the therapeutic effect.

关 键 词：晚期乳腺癌 循环肿瘤细胞 波形蛋白 蛋白激酶B1 

分 类 号：R737.9[医药卫生—肿瘤] R730.43[医药卫生—临床医学]